- Home
- CBIO vs UMAC Comparison
CBIO vs UMAC Comparison
Compare CBIO & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- UMAC
- Stock Information
- Founded
- CBIO 2003
- UMAC 2019
- Country
- CBIO United States
- UMAC United States
- Employees
- CBIO N/A
- UMAC N/A
- Industry
- CBIO
- UMAC
- Sector
- CBIO
- UMAC
- Exchange
- CBIO Nasdaq
- UMAC Nasdaq
- Market Cap
- CBIO 308.0M
- UMAC 267.7M
- IPO Year
- CBIO N/A
- UMAC 2024
- Fundamental
- Price
- CBIO $12.85
- UMAC $10.04
- Analyst Decision
- CBIO Strong Buy
- UMAC Strong Buy
- Analyst Count
- CBIO 3
- UMAC 2
- Target Price
- CBIO $25.67
- UMAC $19.00
- AVG Volume (30 Days)
- CBIO 108.6K
- UMAC 4.8M
- Earning Date
- CBIO 07-31-2025
- UMAC 08-14-2025
- Dividend Yield
- CBIO N/A
- UMAC N/A
- EPS Growth
- CBIO N/A
- UMAC N/A
- EPS
- CBIO N/A
- UMAC N/A
- Revenue
- CBIO N/A
- UMAC $6,988,704.00
- Revenue This Year
- CBIO N/A
- UMAC $100.69
- Revenue Next Year
- CBIO N/A
- UMAC $93.15
- P/E Ratio
- CBIO N/A
- UMAC N/A
- Revenue Growth
- CBIO N/A
- UMAC 1029.19
- 52 Week Low
- CBIO $10.90
- UMAC $1.28
- 52 Week High
- CBIO $21.40
- UMAC $23.62
- Technical
- Relative Strength Index (RSI)
- CBIO N/A
- UMAC 52.41
- Support Level
- CBIO N/A
- UMAC $9.51
- Resistance Level
- CBIO N/A
- UMAC $11.08
- Average True Range (ATR)
- CBIO 0.00
- UMAC 0.78
- MACD
- CBIO 0.00
- UMAC -0.14
- Stochastic Oscillator
- CBIO 0.00
- UMAC 45.19
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.